Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2020

Uncovering tumour heterogeneity through PKR and nc886
analysis in metastatic colon cancer patients treated with 5-FUbased chemotherapy
María Belén Ortega-García
Instituto de Investigación Biosanitaria ibs.GRANADA

Igor Zwir
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Ortega-García, María Belén; Zwir, Igor; and et al, ,"Uncovering tumour heterogeneity through PKR and
nc886 analysis in metastatic colon cancer patients treated with 5-FU-based chemotherapy." Cancers
(Basel). 12,2. . (2020).
https://digitalcommons.wustl.edu/open_access_pubs/8797

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

cancers
Article

Uncovering Tumour Heterogeneity through PKR and
nc886 Analysis in Metastatic Colon Cancer Patients
Treated with 5-FU-Based Chemotherapy
María Belén Ortega-García 1,2,3,4 , Alberto Mesa 5 , Elisa L.J. Moya 1 , Beatriz Rueda 6 ,
Gabriel Lopez-Ordoño 7 , Javier Ángel García 2 , Verónica Conde 2 , Eduardo Redondo-Cerezo 8 ,
Javier Luis Lopez-Hidalgo 6 , Gema Jiménez 1,3,4 , Macarena Peran 4,9 ,
Luis J. Martínez-González 10 , Coral del Val 1,5,11 , Igor Zwir 1,5,11,12 ,
Juan Antonio Marchal 1,3,4,13, * and María Ángel García 1,3,4,14, *
1

2
3
4
5
6
7
8
9
10
11
12
13
14

*

Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain;
bgorteg@correo.ugr.es (M.B.O.-G.); elisajimenezmoya@correo.ugr.es (E.L.J.M.); gemajg@ugr.es (G.J.);
delval@decsai.ugr.es (C.d.V.); jorgezwir@wustl.edu (I.Z.)
Department of Oncology, Virgen de las Nieves University Hospital, 18014 Granada, Spain;
javier.garcia.garcia.sspa@juntadeandalucia.es (J.Á.G.); veronica.conde.sspa@juntadeandalucia.es (V.C.)
Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research, (CIBM)
University of Granada, 18100 Granada, Spain
Excellence Research Unit “Modelling Nature” (MNat), University of Granada, 18071 Granada, Spain;
mperan@ujaen.es
Andalusian Research Institute in Data Science and Computational Intelligence (DaSCI Institute),
18014 Granada, Spain; alber12@correo.ugr.es
Department of Pathology, San Cecilio University Hospital, 18016 Granada, Spain;
beatriz.rueda.sspa@juntadeandalucia.es (B.R.); javierl.lopez.sspa@juntadeandalucia.es (J.L.L.-H.)
Department of Gastroenterology, Torrecardenas Hospital, 04009 Almería, Spain;
gabriel.lopez.sspa@juntadeandalucia.es
Department of Gastroenterology, Virgen de las Nieves University Hospital, 18014 Granada, Spain;
Eduardo.redondo.sspa@juntadeandalucia.es
Department of Health Sciences, University of Jaén, 23071 Jaen, Spain
GENYO: Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional
Government, PTS, 18007 Granada, Spain; luisjavier.martinez@genyo.es
Department of Computer Science and Artificial Intelligence, University of Granada, 18071 Granada, Spain
Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
Department of Human Anatomy and Embryology, University of Granada, 18016 Granada, Spain
Department of Biochemistry and Molecular Biology III, University of Granada, 18016 Granada, Spain
Correspondence: jmarchal@ugr.es (J.A.M.); mangelgarcia@ugr.es (M.Á.G.)

Received: 15 January 2020; Accepted: 4 February 2020; Published: 7 February 2020




Abstract: Colorectal cancer treatment has advanced over the past decade. The drug 5-fluorouracil
is still used with a wide percentage of patients who do not respond. Therefore, a challenge is the
identification of predictive biomarkers. The protein kinase R (PKR also called EIF2AK2) and its
regulator, the non-coding pre-mir-nc886, have multiple effects on cells in response to numerous types
of stress, including chemotherapy. In this work, we performed an ambispective study with 197
metastatic colon cancer patients with unresectable metastases to determine the relative expression
levels of both nc886 and PKR by qPCR, as well as the location of PKR by immunohistochemistry
in tumour samples and healthy tissues (plasma and colon epithelium). As primary end point, the
expression levels were related to the objective response to first-line chemotherapy following the
response evaluation criteria in solid tumours (RECIST) and, as the second end point, with survival
at 18 and 36 months. Hierarchical agglomerative clustering was performed to accommodate the
heterogeneity and complexity of oncological patients’ data. High expression levels of nc886 were
related to the response to treatment and allowed to identify clusters of patients. Although the PKR
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mRNA expression was not associated with chemotherapy response, the absence of PKR location
in the nucleolus was correlated with first-line chemotherapy response. Moreover, a relationship
between survival and the expression of both PKR and nc886 in healthy tissues was found. Therefore,
this work evaluated the best way to analyse the potential biomarkers PKR and nc886 in order to
establish clusters of patients depending on the cancer outcomes using algorithms for complex and
heterogeneous data.
Keywords: colorectal cancer; 5-fluorouracil-based chemotherapy; protein kinase PKR; non-coding
nc886; ambispective study; cluster of patients; biomarkers

1. Introduction
Colorectal cancer (CRC) is one of the most common forms of cancer worldwide, being the third
most commonly diagnosed malignancy and the second leading cause of cancer death in recent years [1].
Although CRC treatment has advanced over the past decades, treatment outcomes depend, in part, on
tumour- and patient-specific molecular characteristics [2]. Even though many novel drugs have been
developed for patients with advanced CRC, 5-fluorouracil (5-FU) is still widely used as the classic
and basic drug in adjuvant chemotherapy and palliative care. 5-FU is used as an infusion, taken
orally (capecitabine), or used in combination with different drugs (FOLFOX, FOLFIRI) but its efficacy
is limited by numerous factors including tumour cell genetics, epigenetics, and proteomics, which
promote chemoresistance and metastasis [2]. In the last decade, the efficacy of these regimens has been
increased by incorporating new biological therapies based on the use of monoclonal antibodies [3].
Despite the fact of the considerable improvement in the efficacy, there are still a wide percentage of
patients who do not benefit from 5-FU-based treatments. Therefore, the identification of biomarkers
that associate or predict the benefit of an appropriate selection of candidates for 5-FU-based therapies
and combined therapies constitutes a broad area in clinical and translational research.
The protein kinase R (PKR, also called EIF2AK2) is an interferon-inducible double-stranded
RNA protein kinase with multiple effects on cells. This protein kinase plays an active part in the
cellular response to numerous types of stress mediating in several biological pathways and with
a potent role in the induction of apoptosis in response to numerous compounds [4]. PKR is a
serine-threonine kinase, composed by the kinase domain shared by the other eukaryotic initiation
factor 2 alpha (eIF2α) kinases, and two dsRNA binding domains (dsRBD) that regulate its activity.
PKR autophosphorylation represents the activation reaction that leads to the phosphorylation of
eIF-2α, impairing eIF-2 activity, which results in the inhibition of protein synthesis [5]. In addition
to its translational regulatory function, PKR has a role in signal transduction and transcriptional
control through the IκB inhibitor/ nuclear transcription factor NF-κB pathway [6]. Although the
primary PKR activator is dsRNA—produced during infection by several viruses and detected at low
levels in mammalian cells—PKR is also activated by a variety of cellular stresses including cytokines,
calcium stress, oxidative stress, endoplasmic reticulum stress, lipo-stress, amyloid-β (Aβ) peptide
accumulation, polyanions such as heparin, and several drugs, or through the PKR-associated activator
(PACT) [7]. PKR, which is expressed constitutively in mammalian cells, has also been implicated
in the control of cell growth and differentiation with debated antitumor role and as an important
antiviral agent [7]. Recently, the role of PKR related to metabolism, inflammatory processes, cancer,
and neurodegenerative diseases has gained great interest [7,8].
The importance of PKR function in cell growth, differentiation, stress response, and
immunomodulation is further noted by the existence of numerous modulators. Therefore, it has
been identified that several PKR regulators are involved in cancer outcome, where the non-coding
RNA pre-miR-886, also called nc886 or vault vtRNA 2-1, has been described as a potent regulator
of PKR [9–11]. Nc886 binds to PKR with an affinity comparable to dsRNA and prevents PKR from
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being activated, in contrast to the PKR-activating ligand dsRNA [9–11]. Although nc886 was initially
discovered as a PKR inhibitor, recently researchers have demonstrated that nc886 can adopt two
structurally distinct conformers that are functionally opposing regulators of PKR [12,13].
We have previously identified PKR as a molecular target of 5-FU in several colon and breast
cancer cells lines, playing an important role in the cytotoxic effect of 5-FU at least, in part, through the
induction of cell death by apoptosis [14]. Because PKR has also been implicated in the anti-tumour
activity of chemotherapeutic drugs such as doxorubicin (DOX) and etoposide [15,16], and nc886 has
been identified as an interesting tumour suppressor [17–19], we consider the analysis of PKR and the
nc886 in patients as potential predictive biomarkers to be of clinical importance. For this reason, the aim
of this work was to carry out an ambispective study in 197 metastatic colon cancer patients to evaluate
the expression levels of PKR and its pre-microRNA-nc886 by qPCR in colon tumour samples and their
respective healthy tissues and plasma, analysing its relation with the patient’s clinical evolution. The
primary end point was the evaluation of these variables with the objective response (OR) to first-line of
5-FU-based chemotherapy determined by the response evaluation criteria in solid tumours (RECIST).
As the second end point, we also analysed the relationship of these variables with overall survival
(OS) at 18 and 36 months in those patients when the information was available. In addition, we
analysed the PKR location by immunohistochemistry in 76 colon tumours and its respective colon
healthy tissues. For all of this study, novel bioinformatic analyses have been included in order to
distinguish parameters and signals for the identification of different profiles in patients, who have the
same diagnostic and disease. Hence, clustering analyses were done using hierarchical agglomerative
clustering (Statistical Toolbox, Matlab 2007, Spotfire Decision Site 9.1.2) [20], with the objective of
improving the quality and specificity of the results considering the heterogeneity between samples
and the genetic and proteomic background of oncologic patients.
2. Materials and Methods
2.1. Patients and Samples
The study was approved by the Biomedical Research Ethics Committee of Granada (Cod Peiba.
0170-N-16) and informed patient consent was obtained. The process of recruitment, traceability of
samples, and informed consent was regulated and controlled by the Andalusian Public Health System
Biobank (BBSSPA), according to the World Medical Association Declaration of Helsinki.
The study included a total of 197 colon metastatic cancer patients with unresectable lung or liver
metastases from September 2014 through to September 2018 who were treated with 5-FU-based therapy
as first-line treatment using the standard treatment schedule. To avoid discarding as few samples as
possible, the missing values were approximated to the median value established for each variable
analysed (see the supplementary Excel document with available data in Figure S1). Criteria of the
RECIST guidelines were used to characterize the response to this treatment [21,22]. According to
these criteria, after the first restaging assessment that was generally performed around 3–4 months
after the initiation of 5-FU-based treatment, patients with progressive disease were considered as
non-responders with primary resistance and those patients with partial response or stable disease under
the 5-FU treatment for at least 3–4 months were considered as responders. Survival was considered
after 18 months and 36 months in those patients where the data were available (see the supplementary
Excel document with available data in Figure S1).
Tumours were classified according to the 2002 tumour, node, metastasis (TNM) classification
and the Fuhrman grading system by experienced pathologists (B.R. and J.L.L.-H.) [23]. Archived
formalin-fixed paraffin-embedded (FFPE) tissue samples from colon tumour and their corresponding
surrounding healthy colon tissues obtained for routine diagnostic purposes were used in this study.
Peripheral blood samples of subjects were collected prospectively with one tube for EDTA anticoagulant
(3 mL). Samples were centrifuged at 3000 rpm for 10 min and, then, aliquoted and frozen at −80 ◦ C until
use. The flow diagram shown in Figure 1 outlines the steps performed in this ambispective study.
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2.4. Immunohistochemistry Analysis
Formalin-fixed paraffin-embedded samples (n = 76) were cut at 2.5 µm in thickness and placed on
a slide. The antigenic retrieval was carried out by incubating the antibody for 30 min with hydrogen
peroxide (H2 O2 ) at pH 8. The immunohistochemical technique was carried out on the Lab Vision
Autostainer 480S (Thermo Fisher Scientific, MA, USA). For the development of the technique, the
Commercial Kit Detection System Master Polymer Plus (Peroxidase) was used. The polyclonal anti-PKR
antibody was administered by Santa Cruz Biotechnology, and it was used with a 1:50 dilution in 30 min
of incubation. The development of the technique was carried out with diaminobenzidine (DAB) and
after, with hematoxylin and eosin staining. The immunohistochemical location of the PKR protein was
determined by two pathologists that considered the presence of the PKR protein in the nucleolus or
outside of nucleolus (mostly located in cytoplasm).
2.5. Machine Learning and Statistical Analysis
PGMRA is a deep unsupervised [28,29] and data-driven machine learning method that combines
model-based, consensus, fuzzy, possibilistic, relational, optimization, and conceptual clustering techniques
into a single method (see the supplementary material in [30] for a review, [20,31]). The model-based
approach uses non-negative matrix factorization to identify candidates for functional clusters [20,32]
represented as tensors or flattened biclusters (e.g., subjects × symptoms). Biclusters can be learned
independently of the number of clusters, and thus, from different granularity partitions (consensus).
The method separately searches for biclusters in distinct domains of knowledge (e.g., genetics, clinical
symptoms) without regard for their calculations in other domains of knowledge [33]. Then, the approach
agnostically co-clusters the inter-domain biclusters and identifies natural relationships (associations)
among them. Associations result from optimizing the probability of the intersection among biclusters using
hypergeometric statistics or Fisher’s exact test [34,35] evaluated by a posterior permutation test instead of
using typical inter/intra clustering metrics among dots in the n-dimensional space (model-based). Biclusters
in one domain of knowledge or associations of biclusters from different domains of knowledge can be
reorganized into networks at different levels of granularity, connected by sharing observations (subjects)
and/or features (∆ct mean values, objective first-line chemotherapy response). This framework constitutes
a knowledge base and characterizes architecture of the disease. The methodological basis of PGMRA
is available in [20,31,34–36], and its web server application is online at http://phop.ugr.es/fenogeno [20].
Fast parallel software implementations were run at the Centre for High Performance Computing (CHPC)
facility at Washington University School of Medicine (WUSM).
2.6. Derivation of the Empirical Index
First, we calculated a purely empirical (i.e., agnostic and data-driven) indicator of character
functioning. We clustered subjects corresponding to the two expression variables and assigned each
subject the number of the cluster to which they belonged (as described in the next paragraph). The
result was a single empirical index of cluster membership that served as a comprehensive measure of
variability in the RNA expression.
To calculate the cluster rankings, we applied hierarchical agglomerative clustering (Statistical
Toolbox, Matlab 2007b) [20] with a complete linkage method and correlation similarity measurement to
group value phenotypic or environmental sets by their shared subjects using hypergeometric statistics.
The function that controls the vertical order in which a row is plotted (Spotfire Decision Site 9.1.2) in a
hierarchical clustering is defined as follows.
Given two sub-clusters within a cluster (there are always exactly two sub-clusters considered at
each step), both sub-clusters are weighted and the sub-cluster with the highest weight is placed above
the other sub-cluster. This function is systematically applied until a single cluster containing all rows
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is obtained. To calculate the weight w3 of a new cluster, C3 is formed from two sub-clusters C1 and C2
with a weight of w1 and w2 , and each containing n1 and n2 rows, and the following expression is used:
w3 =

n1 x w1 + n2 x w2
( n1 + n2 )

(1)

The weight of a sub-cluster with a single row is calculated as the average value of its columns.
2.7. Feature Selection Process Using Non-Negative Matrix Factorization (NMF) in PGMRA
We use non-negative matrix factorization (NMF) method as a deep autoencoder [29] in a particular
domain of knowledge (qPCR data, clinical data) to identify candidates for functional clusters [20,32],
represented as tensors or flattened biclusters (e.g., unknown relationships embedded in the data (subjects
× non-coding RNA differential expression)). Our implementation of the NMF, termed fuzzy NMF
method (FNMF), learns [20,30] biclusters independently of the number of clusters, and thus, from different
granularity partitions (consensus). The method separately searches for biclusters in distinct domains of
knowledge without regard for their calculations in other domain of knowledge [33]. Then, the approach
agnostically co-clusters the inter-domain biclusters and identifies natural relationships (associations)
among them. Associations result from optimizing the probability of the intersection among biclusters
using hypergeometric statistics instead of using typical inter/intra clustering metrics among dots in
the ndimensional space (model-based). These associations are learned regardless of any status of the
observations (e.g., cases and controls, unsupervised) and are optimized on the basis of multiobjective
and multimodal optimization techniques [37]. By incorporating a posteriori, a “supervised” status, the
method is able to calculate the risk of the association by the frequency of one status vs. another. Once it
occurs, the method becomes semi-supervised, and posterior statistical significance of the association is
calculated using kernel-based and multivariate statistical analyses [20,38].
3. Results
3.1. Normalized Values of Non Coding nc886 in Plasma and Tumor Tissues Predicted the Objective First-Line
Chemotherapy Response
We tested first the association of the expression level of the PKR gene and the nc886 RNA molecule
determined by the ∆ct mean values identified by qPCR in tumour (T), plasma (P), and healthy (S)
tissues (see the supplementary Excel document in Figure S1) with the OR to first-line chemotherapy.
The response was encoded as a Boolean (positive/responders, negative/non-responders) tested after
3–4 months of starting the treatment as indicated in the Material and Methods section.
We identified two biclusters (subjects sharing subsets of features) composed of subjects sharing
P-nc886 ∆ct mean and T-nc886 ∆ct mean values (Figure 2A). These biclusters exhibited significantly
different values of their composite features (Figure 2B, p < 2.44655 × 10−77 ANOVA statistics).
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3.3. Final Outcome Was Predicted by the Expression Level of PKR and nc886 in Healthy Tissues
Finally, we raised the question about the correlation between the OR to first-line chemotherapy and
the time-range patient survival after 18 and 36 months. To test the predictability effect of the measured
variables, we first applied the PGMRA method to separately factorize these three measurements using
NMF and we uncovered three biclusters, now called “survival clusters” (Figure 5A). Survival cluster 1
involved patients who mostly showed a negative response to the first line of treatment and died before
18 months (Figure 5A). Survival cluster 2 included patients who mostly showed a positive response to
the first line of treatment and were alive after 18 months; however, they died before reaching 36 months
(Figure 5A). Survival cluster 3 involved all patients who mostly showed a positive response to the first
line of treatment and were alive after 18 and 36 months (Figure 5A).
On the other hand, independently, PGMRA selected the expression values of PKR and the nc886
in P, T, and S for two biclusters (Figure 5B). We found two clusters based on colon healthy tissue values
from PKR and nc886, from now on called S-PKR_S-nc886 clusters. S-PKR_S-nc886 cluster 1 included a
large number of patients mostly with low ∆ct mean values for nc886 and PKR. S-PKR_S-nc886 cluster
2 included fewer number of patients mostly with high ∆ct mean values for nc886 and PKR (Figure 5B).
These S-PKR_S-nc886 biclusters exhibited significantly different values of their composite features
(Figure 5C, p < 2,48689 × 10−136 ANOVA statistics).
Finally, we co-clustered the S-PKR_S-nc886 clusters with the survival clusters, identifying two
significant associations. The most representative bicluster displayed low nc886 ∆ct mean values and
medium PKR ∆ct mean values in healthy tissues (Figure 5D). This cluster was associated with a
positive objective first-line chemotherapy response, and a long time-range patient survival (Figure 5D,
p < 0.014, hypergeometric statistics/Fisher’s tests). Therefore, higher expression levels of nc886 once
again selected patients with better disease outcomes. The other significant bicluster exhibited high
∆ct mean values in healthy colon tissue of the two variables PKR and nc886 (Figure 5D), and was
associated with negative objective first-line chemotherapy response and short survival (Figure 5D,
p < 0.016, hypergeometric statistics/Fisher’s tests). Therefore, lower expression levels of nc886 and
PKR in healthy colon tissue selected patients with worst disease outcomes. A non-significant survival
bicluster exhibiting a mixture survival values was not significantly associated with nc886 and PKR ∆ct
mean values in healthy tissues (Figure 5D).
The three survival classes were independently validated using regression analysis with the clusters
(rankings, see the Materials and Methods section) of healthy tissue nc886 ∆ct mean values and the
healthy tissue PKR ∆ct mean values (p < 0.0053, F statistics).
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Table 1. Clusters of patients associated with objective first-line chemotherapy response and with overall
survival at 18 and 36 months.
Sex
Metastatic Colon Cancer Patients

Total
197

Firs-line Chemotherapy Response
clusters (OR)
P-nc886_S-nc886
Cluster
1
Cluster
2
S-PKR_S-nc886
Cluster
1
Cluster
2

Female

127

70

Age (Mean Years), SD
65.1 ± 10.5
∆ct mean values, SD

Total
197

Responders(+)
128

T-nc886

P-nc886

160

110

50

0.427 ± 0.09

0.289 ± 0.05

37

18

19

0.567 ± 0.17

0.495 ± 0.14

S-nc886

S-PKR

77
14

Survival

Non-Responders(-)
69

45

32

0.386 ± 0.12

0.465 ± 0.09

6

8

0.682 ± 0.09

0.703 ± 0.16

OS 18 m

OS 36 m

Survival Exitus

Survival Exitus

First-line
Response
+
-

Survival clusters (OS)
Cluster
1
Cluster
2
Cluster
3

Male

26

0

26

0

26

0

26

18

15

3

12

6

0

18

47

36

11

47

0

47

0

In order to group patients sharing similar features within the existing heterogeneity, we approached
this ambispective study using NMF techniques encoded into the PGMRA system [20]. This system
was successfully used to identify complex genotypic–phenotypic architecture of mental disorders and
personality traits [40], which has now been customized for cancer phenotypes. In contrast to classical
clustering techniques, not all features are included in such associations, but only those that provide
a multifaceted description of groups of patients at risk. These meaningful associations are termed
biclusters [20,34].
When analysing the ∆ct mean values of nc886 in P and T, we identified two biclusters composed
of subjects sharing ∆ct mean values of T-nc886 and P-nc886 that were associated with the OR to
first-line chemotherapy. We found a significant association between patients with high levels of nc886
expression in both P and T, as well as a positive primary response to treatments based on 5-FU. Our
results are consistent with previous results that show that nc886, as a Pol III transcript, is expressed
abundantly and ubiquitously in all normal human tissues [41] and that its expression is increased in
cancer cells [42]. In fact, most patients in our study expressed high levels of nc886 when considering
the ∆ct mean values obtained in tumours (Table 1). The tumour suppressor role of nc886 has been
already previously related to a better prognosis of the disease in several neoplasia such as lung, ovarian,
and breast cancer, among others [17,19,43–45], but this study was the first time that has been related
to CRC.
Moreover, we identified a smaller second significant cluster associating patients that showed a
negative response to first-line treatment with lower levels of nc886 expression in the tumour. This result
agrees with the previous results, where the expression of nc886 was found to be diminished or silenced
in a subset of malignant cells by the DNA hypermethylation of its promoter’s CpG island [17–19,44,45].
Although we did not analyse the level of silencing of nc886, our results are consistent with the poor
outcome detected during nc886 epigenetic repression in several neoplasms, supporting the role of
tumour suppressor of nc886 also in colon cancer disease.
The levels of PKR mRNA expression could not be associated to chemotherapy response in our
analysis. The Ser/Thr kinase PKR is a non-canonical kinase involved in many cellular pathways
exerting various functions on cell growth and tumorigenesis [4,7,8]. Although there have been multiple
studies of PKR, the exact role in cancer biology remains controversial. This is due on one hand to its

Cancers 2020, 12, 379

13 of 17

ability to induce eIF2α-mediated apoptosis and on the other hand to NF-κB-mediated pro-survival
effect, involved in both tumour-suppressive or oncogenic roles [6–8,11,14]. Because we previously
identified PKR as a molecular target of 5-FU in several colon cancer cells lines [14] playing an important
role in the cytotoxic effect of 5-FU, through the induction of apoptosis, in a PKR expression-dependent
manner, we expected a high expression level of the PKR gene in responder patients. However, the
high level of post-translational modifications and regulation of the protein indicated that PKR activity
does not necessarily have to correspond to the amount of its messenger RNA. In fact, numerous
proteins have been described as regulating their activity (e.g., PACT, trans-activation response (TAR)
RNA binding protein (TRBP), nucleophosmin (NPM)) [4,7,8,46–48] and several post-translational
modifications have been showed by SUMOylation and ISGylation, among others [49,50]. Nc886 has
been described as a PKR inhibitor, being the inhibition of PKR/NF-kB in correlation with its tumour
suppressor activity. However, recently researchers have demonstrated that nc886 can adopt two
structurally distinct conformers that are functionally opposing regulators of PKR that have a second
conformation able to activate PKR [12]. Therefore, whether a high level of nc886 is related to a best
response to 5-FU treatment that corresponds with a high ability of PKR to induce apoptosis is still
unknown and needs further investigation. In addition, a different location of PKR in the nucleus and
nucleolus has been demonstrated with different forms that also suggest differences in its activity [51,52].
It has been described that PKR localizes in the cytoplasm, strongly in the nucleolus, and diffusely
throughout the nucleoplasm [52]. Our analysis of total PKR expression by immunohistochemistry
in 76 samples of colon tumour and their respective healthy colon tissues showed expression in the
cytoplasm in all healthy tissues and in most of the colon tumour analysed. However, a smaller group of
tumours were shown diffuse staining in the nucleus and, above all, staining was restricted exclusively
to the nucleolus. The PGMRA analysis considering the presence or absence of PKR in the nucleolus
found a bicluster where patients with PKR located in tumour cytoplasm (and absent in the nucleolus)
were related with OR to first-line chemotherapy. A cluster included patients whose PKR location
in the cytoplasm of the tumour cells corresponded with a positive response to the treatment, and
although the levels of expression of PKR and nc886 analysed were variable between samples, they
were necessary to establish statistically significant clusters. In contrast, patients with PKR restricted to
the nucleolus in the tumour could be grouped significantly in a cluster that corresponded with the
negative response to treatment. Therefore, an increase in the number of samples to be analysed would
be convenient in future research to specifically relate the levels of nc886 with the location of PKR and
the response to treatment. Although the role that PKR activity may have in the nucleus/nucleolus is not
yet known, it has been suggested that PKR exists in leukaemia cell lines and patient samples in diverse
molecular weight forms in the nucleus as result of several post-translational modifications. Although
cytoplasmic location was detected in leukaemia low-risk patients, nuclear location was restricted to
high-risk patients [51]. In addition, intrahepatic PKR nucleolar labelling was observed in human blood
PBMCs and liver biopsies, with a suggested ribosome biogenesis role [53].
Finally, we found different survival clusters in those patients for which information was available
(Table 1), allowing for the grouping of patients according to the expression of nc886 and PKR in healthy
colon tissue. Interestingly we found two clusters significantly related to the outcome of the patients;
the most representative cluster included patients with higher expression levels of nc886 and medium
expression levels of PKR in the healthy colon tissues who were alive after 3 years of the first-line
treatment. In contrast, lower levels of expression of both PKR and nc886 in healthy colon tissue were
related with patients who died at a year and a half after the first-line treatment. Although PKR levels
did not appear to be related to their activity, as we have previously discussed, for tumour cells, they
interestingly remained average in healthy tissue in the cluster of patients with the best outcome, and
showed less expression in healthy tissue for the cluster with worse outcome. The role of PKR as a
cellular stress response protein is widely known, as PKR intervenes against numerous and varied
infections, also eliminating damaged cells inducing apoptosis. In addition, PKR is able to allow the
cells to live via NF-kB activation once the stress has been resolved on time [4,7,8,13]. Moreover, PKR
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also regulates some tumour suppressors and protein kinases involved in cancer pathways such as
the signal transducers and activators of transcription factors (STATs), activating transcription factors
(ATFs), tumour suppressor p53 (Tp53), the phosphatase and tensin homologue tumour suppressor
(PTEN), the mitogen-activated protein kinases (MAPKs), and the toll-like receptors (TLRs), among
others [4,7,8,13]. All these data suggest how important it is that PKR is expressed at adequate levels in
normal tissue where it would be slightly regulated, as well as the importance that PKR would have in
tumours where, regardless of its expression, its regulation can be critical.
5. Conclusions
In summary, although it would be convenient to increase the “n”, especially for studies where
we have had less available data, we can consider that PGMA is a useful system for working with
heterogeneous diseases such as cancer. PGMA analysis allowed us to identify clusters where the levels
of expression of nc886 can be suggested as a potential biomarker for both the first-line response to
chemotherapy and the survival of patients for at least 18 or 36 months. The higher levels of expression
of nc886 in tumours, plasma, and healthy tissues were found in those patients with a better outcome.
Although it is necessary to analyse a greater number of subjects to know the role of PKR as a biomarker,
our data suggest that its location in the tumour cell compartments, but not its mRNA expression level,
could predict the response to treatment based on the use of 5-FU in metastatic colon cancer patients.
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